Lisinopril is under clinical development by Transparency Life Sciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lisinopril’s likelihood of approval (LoA) and phase transition for Relapsing Remitting Multiple Sclerosis (RRMS) took place on 25 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lisinopril Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lisinopril overview

Lisinopril is under development as an adjunctive therapy for the treatment of relapsing remitting multiple sclerosis. It is developed as repurposed drug candidate acts by targeting angiotensin converting enzyme.

Transparency Life Sciences overview

Transparency Life Sciences (TLS) is a clinical research technology company to improve human health by including patients in trial design, offering convenient access to trials, generating more relevant and informative data, and reducing the costs of drug development. Transparency Life Sciences is headquartered in New York, New York, the US.

Quick View Lisinopril LOA Data

Report Segments
  • Innovator
Drug Name
  • Lisinopril
Administration Pathway
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.